Group B streptococci in human disease.
Group B streptococci in human disease.
复制标题
人类疾病中的 B 族链球菌。
作者：
M. Patterson;Anees EL Batool
引言.774历史和名称.774人类疾病......................774代理人.775株牛和人类来源的菌株.......775血清分类.........775毒力因数......................776新陈代谢777临床疾病谱.......777及早承认.....................777新生儿疾病.778年龄较大的儿童及成人的疾病.........779发病机制.....................779围产期移居.779出生后殖民.780实验室诊断.....................780用于初步分离的选择性肉汤培养基.............780推定身分..781血清学鉴定...782免疫学......................................782宿主抗体反应...........782白细胞反应........783流行病学......................................783事件......783来源.784变速箱......................................784微生物持久性........784种族......................................785性.......785其他因素.785预防和治疗......785抗菌药物敏感性谱.....................................785承运人预防.....................................785结束语...787文献被引用........七百八十七
INTRODUCTION .............................. 774 History and Nomenclature .............................. 774 Human Disease .............................. 774 THE AGENT .............................. 775 Strains of Bovine and Human Origin ............ .................. 775 Seroclassification .............................. 775 Virulence Factors .............................. 776 Metabolism .............................. 777 CLINICAL DISEASE SPECTRUM ......... ..................... 777 Early Recognition ............................. 777 Neonatal Disease .............................. 778 Disease in Older Children and Adults .......... ................... 779 PATHOGENESIS .............................. 779 Perinatal Colonization .............................. 779 Postnatal Colonization ............................. 780 LABORATORY DIAGNOSIS ............................. 780 Selective Broth Medium for Primary Isolation ................................. 780 Presumptive Identification ............ ......................... 781 Serological Identification .......... ........................... 782 IMMUNOLOGY ...................................... 782 Host Antibody Response .......... ........................... 782 Leukocytic Response ........ ............................. 783 EPIDEMIOLOGY ...................................... 783 Incidence ...................................... 783 Source ...................................... 784 Transmission ...................................... 784 Microbial Persistence ......... ............................ 784 Race ...................................... 785 Sex ..................................... 785 Other Factors ...................................... 785 PROPHYLAXIS AND TREATMENT ...................................... 785 Spectrum of Antimicrobial Susceptibility ..................................... 785 Carrier Prophylaxis ..................................... 785 CONCLUDING REMARKS .......... ........................... 787 LITERATURE CITED ........ ............................. 787